A venture capital firm with offices in Boston, Massachusetts and San Francisco, California has raised a $470 million oncology impact fund through a joint venture. The firm typically makes investments ranging from $3 to $25 million depending on the target company’s stage of development and capital requirements. The firm will consider investment into companies located anywhere around the globe. The firm makes 3-4 new investments annually.

The firm is currently focused on companies developing therapeutics, in particular oncology and regenerative medicine, however they will also consider investments into companies developing platform technologies. While the firm considers investment from seed stage to PIPE (private investment in public equity) the firm’s ideal company has an asset that is pre-clinical or in early clinical trials.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

An international corporation in the imaging sector has established 5 innovation investment offices worldwide.  The firm seeks to make Seed to Series A investments of less than $5 million for less than 20% equity in private companies. Collaborative R&D can also be considered. The firm is currently looking for opportunities around the world.

The innovation investment program seeks to strengthen the firm’s core imaging business, explore new areas of innovation, and identify key players in their focused ecosystems. Within healthcare, the firm focuses on telemedicine and connected device solutions for applications such as patient management and virtual clinics. The firm considers products that have completed prototypes or achieved proof of concept with a clear path to FDA clearance (for 510K devices).

The firm closely collaborate with a diverse range of entities, such as academic institutes, research institutes, partner companies, and startups. The firm would like to obtain distribution rights in Japan; however, this is not a requirement for collaboration.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

A family office invests from an evergreen fund focused on seed to later-stage companies building infrastructure and value chains around big data, including but not limited to health and life science data. Typical investment sizes range from $250K – $1M for early-stage companies. Additional capital for follow-on investments is available for portfolio companies. Along with capital, the firm also provides access to their Asian network for later-stage companies needing market expansion (once all other aspects of the company’s business have been resolved). There is not a requirement for a board seat along with investments.  The fund is focused on U.S. companies (with a focus on Silicon Valley), but will consider companies globally.

The firm invests in companies that are creating solutions to close the data feedback loop, including capturing data, analytics and instruments/robotics. The firm is interested in medical devices, diagnostics and healthcare IT products, with addressable markets of at least $1B. In the diagnostics field, m-health devices and genomics are of particular interest. AME is open to all sub-sectors of health IT including consumer-facing hardware/software, data collection/management and data analytics. The firm will invest in medical devices and diagnostics that require FDA approval, with 510K regulatory pathway being the most common, although devices/services that require different regulatory pathways will also be considered. Companies developing hardware or robotics that automate scientific life science experiments are also of interest. The firm does not make any investments in therapeutics.

There are no formal requirements for management teams, but management teams with experience commercializing products are preferred.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

A venture capital firm based in Europe focused solely on the life sciences has recently closed a new fund and is actively looking for investments, usually in series A rounds. Typically, the firm allocates €8M-€10M over the life of the investment with about half of that amount up front, in the initial investment. The firm primarily invests in companies that are based in mainland Europe, but will also consider opportunities in North America.

The firm invests solely in biotech therapeutics and medical devices. For biotech, the firm invests in pre-clinical up unto phase II assets. For medical devices, the firm prefers companies with with initial clinical proof-of-concept up unto reaching regulatory approval, whether that be PMA or 510(k) approval. The firm is not interested in diagnostic technologies. The firm is agnostic in terms of subsectors and indications, including orphan indications, but is very interested in products that address clear unmet opportunities. Historically, the firm invested in biotech therapeutics that address inflammatory, oncology, respiratory, autoimmune, and cardiovascular disorders. Medical devices include a non-active implantable device for pulmonary embolism, as well as devices for renal and vascular diseases.

The firm requests a board seat in each portfolio company. The firm seeks a company with a strong and experienced management team or technical experts in the relevant technology.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

A family office investment vehicle based in New York City is looking to provide equity capital to high growth companies in the life science space usually in Series A or B rounds. The firms typically deal size is highly variable generally going as high as $5million for an initial investment. and depends on each individuals companies position and funding needs. The firm is currently interested in companies located throughout the US and Canada and is looking to make approximately 2-3 investments over the next year months.

The firm is currently looking for companies developing therapeutics. The firm is opportunistic in terms of sub sector and indication, but has a preference for companies with platform technologies. The firm is not interested in biosimilar or reformulation type opportunities. The firm is willing to invest in companies with a lead asset in preclinical through Phase II of clinical trials.

The firm looks to invest in companies with experienced management teams and is very open to investing in syndicates. The firm is interested in investing into pre-revenue firms, although the firm will not consider making seed stage investments. The firm is capable to act as either a lead or a co-investor and generally seeks board or board observer rights.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com